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ABSTRACT
The Human Phenotype Ontology (HPO) project, avail-
able at http://www.human-phenotype-ontology.org,
provides a structured, comprehensive and well-
defined set of 10,088 classes (terms) describing
human phenotypic abnormalities and 13,326
subclass relations between the HPO classes. In
addition we have developed logical definitions for
46% of all HPO classes using terms from ontologies
for anatomy, cell types, function, embryology,
pathology and other domains. This allows interoper-
ability with several resources, especially those con-
taining phenotype information on model organisms
such as mouse and zebrafish. Here we describe the
updated HPO database, which provides annotations
of 7,278 human hereditary syndromes listed in
OMIM, Orphanet and DECIPHER to classes of the
HPO. Various meta-attributes such as frequency,
references and negations are associated with each
annotation. Several large-scale projects worldwide
utilize the HPO for describing phenotype
information in their datasets. We have therefore
generated equivalence mappings to other pheno-
type vocabularies such as LDDB, Orphanet,
MedDRA, UMLS and phenoDB, allowing integration
of existing datasets and interoperability with
multiple biomedical resources. We have created
various ways to access the HPO database content
using flat files, a MySQL database, and Web-based
tools. All data and documentation on the HPO
project can be found online.
INTRODUCTION
A key challenge in genomics is to understand the pheno-
typic consequence of genomic variation. With the advent
of next-generation sequencing technologies, the challenge
is no longer to generate DNA sequence data, but to inter-
pret them. Currently, the molecular basis of roughly 3700
Mendelian diseases has been elucidated, and a similar
number of named Mendelian or suspected Mendelian
diseases awaits elucidation (1).
The analysis of phenotypic abnormalities provides a
translational bridge from genome-scale biology to a
disease-centered view on human pathobiology. It is
becoming clear that detailed phenotype data, combined
with ever-increasing amounts of genomic data, have an
enormous potential to accelerate the identiﬁcation of clin-
ically actionable complications, of disease subtypes with
prognostic or therapeutic implications as well as to
improve our understanding of human health and disease
(Figure 1).
The description of phenotypic variation is a central
topic for all of those studies, and therefore, a systematic
human and computer interpretable representation is
crucial due to the complex nature of human disease.
Therefore, the usage of standardized measures for
capturing phenotypic abnormalities is of major import-
ance (3), but in the past, it has been difﬁcult to agree on
common semantic and technical standards as well as the
ethical and legal framework for collecting and analyzing
human phenotype data (4).
An ontology provides a conceptualization of a domain
of knowledge, allowing communication between re-
searchers and makes the information readable and ‘under-
standable’ for computers (5). The Human Phenotype
Ontology (HPO) project (6) was initiated in 2007 to
enable sophisticated integration of phenotype information
across scientiﬁc ﬁelds and databases. Since its initial pub-
lication in 2008, the project has grown in terms of
coverage, complexity, usage and cross-linking with other
projects, especially from the Open Biological and
Biomedical Ontologies (OBO) Foundry (7).
THE HUMAN PHENOTYPE ONTOLOGY
The HPO covers a wide range of phenotypic abnormalities
encountered in human disease (Table 1). At the time of
this writing, the HPO contains 10 088 classes (terms) with
13 326 subclass relationships between those classes. The
ontology is organized as three independent subontologies
that cover different categories; the mode of inheritance, the
onset and clinical course and the largest category of pheno-
typic abnormalities.
Each class of the HPO has a unique and stable identiﬁer
(e.g. HP:0002145), a label and a list of synonyms. Most
(6603, 65%) of the classes are accompanied by a detailed
textual deﬁnition created by clinical experts (Figure 2).
Additionally, HPO classes now contain one or more
references to other resources to promote interoperability
among different biomedical research areas. As such, 39%
(3956) of the HPO terms contain cross-references, with
98% of the references pointing to Uniﬁed Medical
Language System and Medical Subject Headings, refer-
ences that are especially helpful for linking to resources
such as the Disease Ontology (8). Other cross-references
include the International Classiﬁcation of Diseases 10th
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revision and the European Paediatric Cardiac Coding list.
Furthermore, ﬂat ﬁles are made available that map HPO
terms to other phenotype vocabularies such as Orphanet’s
Signs and Symptoms (see Section HPO resources and
workﬂow).
To achieve semantic interoperability with other
ontologies from the OBO Foundry (7), the HPO project
began in 2009 to create logical deﬁnitions for each HPO
class. At the time of this writing, we have created these
deﬁnitions for 46% (4591) of all HPO classes. These
logical axioms deﬁne the phenotypic abnormalities based
on classes from other OBO Foundry ontologies (e.g.
anatomy, Gene Ontology process or cell type). They are
formal descriptions, that are machine processable and
usable for automated logical inference and reasoning
(9,10). For example, we have created the following
logical deﬁnition of the HPO term Hypoglycemia
(shown in Manchester syntax):
Class: Hypoglycemia
EquivalentTo:
‘decreased concentration’
and towards some ‘glucose’
and inheres_in some ‘portion of blood’
and qualifier some ‘abnormal’
Here, term identiﬁers are skipped and only term labels
are shown for the purposes of readability. In this example,
the class Hypoglycemia is deﬁned as being equivalent to
the intersection of all classes of things that are ‘A concen-
tration which is lower relative to the normal’ (decreased
concentration from PATO); ‘deviate from the normal or
average’ (abnormal from PATO), with respect to (towards)
glucose and inhering in ‘blood’ [using the term portion of
blood from the Foundational Model of Anatomy (11)].
Deﬁning ontology terms in this way assists in automating
ontology construction, and provides a tool for integrative
computational analysis of human and model organism
phenotypes against the background of the knowledge
incorporated in ontologies such as Gene Ontology,
Foundational Model of Anatomy and Chemical entities
of biological interest (ChEBI) (12–15).
PHENOTYPE ANNOTATION DATA
We provide a large set of phenotype annotations, i.e.
statements that link a particular term from the HPO to
speciﬁc diseases or genes. These annotations are made for
the most speciﬁc term of the HPO, as all of the ancestor
terms are implicitly annotated as well.
At the time of this writing, we provide 110 301 annota-
tions to 7354 diseases listed in the Online Mendelian
Inheritance in Man [OMIM, (16)] database, Orphanet
(17) and DECIPHER (18). On average, each disease
entry has 15 HPO annotations. For Orphanet entries
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Figure 1. The HPO aims to act as a central resource to connect several
genomics datasets with the diseasome. Thus, the HPO can act as a
scaffold for enabling the interoperability between molecular biology
and human disease. For example, phenotypic abnormalities in
genetically modiﬁed model organisms can be mapped to human
disease phenotypes (2).
Table 1. Different types of phenotypic abnormalities covered by the
HPO
‘Class’ of phenotype HPO example
Morphological abnormality Arachnodactyly (HP:0001166)
Abnormal process (organ) Epistaxis (HP:0000421)
Abnormal process (cellular) Abnormality of Krebs cycle
metabolism (HP:0000816)
Abnormal laboratory ﬁnding Glycosuria (HP:0003076)
Electrophysiological abnormality Hypsarrhythmia (HP:0002521)
Abnormality by medical imaging Choroid plexus cyst (HP:0002190)
Behavioral abnormality Self-mutilation (HP:0000742)
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Figure 2. Statistics of the data from the HPO project from January 2009 to August 2013. Ontology statistics shows quantities related to the ﬁle
hp.obo. The annotation statistics clearly demonstrates the inclusion of Orphanet data in October 2012.
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that are exactly mapped to one OMIM entry, we merge
the entries and record the provenance of the annotations.
The annotations of OMIM entries are a mixture of
manual annotations performed by the HPO team and
automated matching of the OMIM Clinical Synopsis to
HPO term labels. The substantial increase in annotation
data during since 2008 is shown in Figure 2.
Each annotation may have several meta-attributes such as
the age of onset, the frequency or a modiﬁer. At the moment,
46 149 annotations have information on the frequency with
which individuals with a given disease have a certain pheno-
typic feature. For instance, 9 of 43 persons with the disease
sialidosis type II have cherry red spot of the macula
(HP:0010729) (19). At the moment, the majority of
frequency annotations are derived from Orphanet, but a
growing number is based on the manual annotation efforts
by the HPO team. Furthermore, we provide a set of 303
negative annotations (NOT-modiﬁer), for which patients
with this disease are known not to have the clinical feature
in question. The frequency and negation information may be
important for the differential diagnosis (20). For 361
annotations, details on the onset are provided. Note that
the onset-information may apply to a disease (e.g.
Marfan syndrome has congenital onset) or to a single pheno-
type annotation (e.g. Kyphosis in Hurler syndrome
(OMIM:607014) has the meta-annotation childhood onset).
Ontologies such as the HPO are not designed to capture
quantitative information such as a blood glucose level of
146mg/dl or an adult body height of 147 cm. Instead,
HPO terms often express qualitative information about
an excess or a reduction in quantity of the entity in
question (i.e., Hypoglycemia and Tall stature). For some
clinical manifestations, however, it has been found to be
clinically useful to divide an entity into two or more
categories. For instance, the degree of intellectual disabil-
ity is often reported as one of the four categories Mild,
Moderate, Severe and Profound. In these cases, the HPO
aims to follow common clinical usage and provide corres-
ponding terms deﬁned according to clinical norms.
Additionally, modiﬁers such as episodic or recurrent are
possible. A summary of meta-annotations and their def-
initions can be found in Table 2.
CLINICAL INTEGRATION AND USE
The HPO project is collaborating with many clinical
groups to reﬁne and extend current terms and
annotations. A major effort was undertaken in 2012
with clinicians from the Deciphering Developmental
Disorders (21) project to ensure that HPO reﬂects the
needs of that project. Efforts were made to eliminate
redundancies and to ﬁll in gaps in the HPO coverage of
organ systems, metabolism, neoplasms, neurology and
behavior. Among other things, the Onset section of the
HPO was revised to provide a small set of well-deﬁned
and non-overlapping terms based on published recom-
mendations (22) (Table 3). Input and collaboration from
other clinical groups will be welcomed.
Whole-exome sequencing (WES) is accelerating the
pace of discovery of novel Mendelian disease genes, but
many challenges remain. A standard strategy for WES
data analysis is to compare variants found in multiple
affected patients. Especially with autosomal dominant dis-
orders, many unrelated individuals must be analyzed for
this strategy to be successful (23). Therefore, one of the
ﬁrst tasks in WES disease gene discovery projects is to
identify multiple patients with the same disease pheno-
type, which has been extremely successful in identifying
novel disease genes even in diseases for which there was
little or no previous knowledge about the characteristics of
the disease gene. However, many of the Mendelian
diseases still waiting to be discovered are very rare or dif-
ﬁcult to diagnose clinically. To make progress on
elucidating these disorders, it will likely be necessary to
combine data from multiple centers to identify a sufﬁcient
number of patients with mutations in the same gene and
comparable phenotypes—which is widely accepted as a
Table 2. Meta-information for HPO phenotype annotations
Meta-attribute Possible values (explanation in brackets)
Qualiﬁer/Modiﬁer not, mild (±2–3 SD from mean), moderate (±3–4 SD from mean), severe (±4–5 SD from mean), profound
(±5SD and greater from mean), secondary, chronic, (non)progressive, episodic, recurrent, bilateral, unilateral,
distal, proximal, refractory and generalized
Evidence Code ITM (inferred by text mining), IEA (inferred from electronical annotation), PCS (published clinical study), ICE
(individual clinical experience), TAS (traceable author statement)
Onset modiﬁer Any term from HPO-subontology Age of onset
Frequency modiﬁer percentage value (e.g. 25%), n of m (e.g. 3/10 patients), very rare, rare, occasional, frequent, typical, variable,
common, hallmark and obligate
The meaning/deﬁnition of the values is shown in brackets. (SD=standard deviation).
Table 3. Deﬁnitions of age-of-onset terms in the HPO
Onset of manifestations Deﬁnition
Less than 1 year
Embryonal <8 weeks’ gestation
Fetal 8 weeks’ gestation–birth
Neonatal Birth–28 days
Infantile 28 days–1 year
More than 1 year
Childhood 1–5 years
Juvenile 5–15 years
Adults
Young adult <40 years
Mid adult 40–60 years
Old age >60 years
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necessary criterion for the identiﬁcation of a novel disease
gene.
This approach has been implemented successfully
for copy-number variation (CNV) disorders in
the International Standards for Cytogenomic Arrays
Consortium’s publicly available database of CNVs
identiﬁed during the course of routine clinical microarray
testing (http://www.ncbi.nlm.nih.gov/dbvar/studies/nstd37/
;https://www.iscaconsortium.org). Recognizing that catalog-
ing the phenotype information associated with each CNV
would be key in trying to elucidate genotype–phenotype
relationships, the group began using HPO terms (as
opposed to free text) to describe the phenotypes in a
manner that was generalizable (to maintain patient ano-
nymity) as well as easily indexable and searchable for the
clinical and research communities (24). Given the success
of this approach, the International Standards for
Cytogenomic Arrays has expanded its focus to include
sequence variation, and, under the name International
Collaboration for Clinical Genomics, will continue to
use HPO terms to describe the phenotypes associated
with results from additional testing modalities, including
WES (25).
A similar approach is also being used by the
DECIPHER project, which enables clinical scientists
worldwide to maintain records of phenotype and chromo-
some rearrangement for their patients and, with informed
consent, share this information with the wider clinical
research community to ﬁnd clusters of rare cases having
phenotype and structural rearrangement in common (18).
The Deciphering Developmental Disorders project of the
Wellcome Trust Sanger Institute has been initiated to use
new genomic technologies including especially WES to
identify novel etiologies for developmental disorders,
and is focused on severe and extreme developmental
phenotypes affecting any organ system, which are coded
using HPO.
An international collaborative study, the Biomedical
Research Centres/Units Inherited Diseases Genetic
Evaluation consortium, will use the HPO database to
record detailed clinical phenotypes of patients with rare
inherited disorders (www.bridgestudy.org). The HPO
database that comprises phenotypes related to
abnormalities in blood and blood-forming tissues has
already facilitated detailed description of the clinical
phenotypes of patients with bleeding and platelet dis-
orders (Biomedical Research Centres/Units Inherited
Diseases Genetic Evaluation-Bleeding and Platelet
Disorders). The homogenization of these clinical pheno-
types related to bleeding and platelet disorders will further
assist in the clustering of data for detailed bioinformatics
analysis of exome sequence data. These patients will be
part of the NIHR Bioresource for Rare Diseases.
The European Cytogeneticists Association Register of
Unbalanced Chromosome Aberrations (ECARUCA,
http://www.ecaruca.net), initiated in 2003, is an online
database that collects and provides detailed, curated
clinical and molecular information on rare unbalanced
chromosome aberrations that are considered to be likely
causative for the patient’s phenotype (26). The objective of
ECARUCA is to improve the knowledge of rare
chromosome aberrations both for medical and research
purposes. Currently, the database contains more than
4800 cases with HPO features characterizing these cases,
and all these data are publicly available to professionals in
genetics.
The Nijmegen Genetics Phenotype Database (NGPD,
https://www.clinicalfeatures.eu/default.aspx) aims to
collect detailed phenotype information of patients with
unexplained intellectual disability and/or congenital
anomalies using the HPO. The goal of the NGPD is to
identify patients who have similar clinical features that are
likely due to the same or a related genetic defect. The
NGPD currently contains more than 8000 patients
with 73 496 HPO features annotated to these patients
(median seven features per patient). Computational
approaches are currently being developed for the identiﬁ-
cation of clusters of phenotypically overlapping patients.
Exome sequencing and targeted candidate gene analysis
will ultimately provide a diagnosis for many of these
patients.
Cartagenia (www.cartagenia.com), a genetics software
solution provider that services diagnostic laboratories
through a set of automated tools for variant interpret-
ation, ﬁltration, reporting and sharing, has standardized
the phenotype functions for clinical patient record anno-
tation of its BENCH laboratory platform on HPO.
Several advantages come by using HPO: automated geno-
type–phenotype correlation, advanced search of patients
within laboratories but also in external databases
(see earlier) and easy sharing of patient phenotype data
among different consortia.
Interoperability between laboratories sharing case
information has beneﬁted from standardization on HPO.
With more than 120 laboratories and clinics using
Cartagenia BENCH in a routine setting, a number of
consortia have emerged where not just genotype but also
phenotype data are shared. Examples include a number of
national consortia sharing variants and phenotype data
(The Netherlands, France, UK and Norway) as well as
disease-speciﬁc registries for (autism, primary immune
deﬁciencies and cardiogenetics), ECARUCA, large
prenatal case registries such as the UK-led NHS EACH
study and a US-led study at the Columbia University,
which have set the phenotyping standard for other
prenatal genotype–phenotype registries.
HPO WORKFLOW AND RESOURCES
As mentioned before, we use a continuous integration
system (Hudson) for the management of stable releases
of the HPO-related data (27) to ensure that users are
provided with up-to-date and validated resources. To
achieve this, only stable builds are made public, and any
curation errors that lead to build failures are detected by
our software and prevented from being propagated onto
the public Web site. For different aspects of the data, we
have generated different jobs and an overview of the job
organization can be found in Table 4. The major focus is
the phenotype ontology and the annotation data, but
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closely related projects such as the cross-species phenotype
ontology Uberpheno (13) are available as well.
The HPO release (job hpo) is triggered whenever
changes in any of the ontology or logical deﬁnition ﬁles
are uploaded. For every build, the OBO Ontology Release
Tool (Oort, https://code.google.com/p/owltools/wiki/
OortIntro) is used to generate OBO- and OWL-format
versions of the HPO. In addition, the GULO software
(28) is used to generate a report on the overlap between
the hierarchy inferred from the logical deﬁnitions and the
manually asserted HPO hierarchy. This is used to incre-
mentally improve both the logical deﬁnitions and the HPO
structure.
Annotation data are also integrated in our Hudson build
system (Table 4). Every HPO release induces a rebuild of
the annotation data (job hpo.annotations). This job
pulls the latest manual annotation data (http://svn.code.sf.
net/p/obo/svn/phenotype-commons/annotations/OMIM/
by-disease/annotated/) and the latest Orphanet data
(http://www.orphadata.org) and constructs one integrated
disease annotation ﬁle. Again only successful builds are
made available, such that e.g. manually curated annota-
tions are automatically checked for consistency before
being offered to the public. The simplest check veriﬁes
the syntactical correctness of the input ﬁles. Another
example is that the generation of annotation ﬁles fails if
there are annotations to obsolete terms, which are terms
that have been marked as to be replaced by other
HPO terms and thus should not be used for annotation
anymore. Another check conﬁrms that annotation
onset-modiﬁers are correctly chosen from the Onset and
clinical course subontology.
Once a month, several secondary ﬁles are created
automatically by the Hudson build system. The job
hpo.annotations.monthly creates an MySQL
version of the HPO and the annotation data. It also
constructs direct gene-to-phenotype mappings, which
use known gene-to-disease relations (from morbidmap
and Orphanet) and disease-to-phenotype relations from
the job hpo.annotations. So for example the gene
ATXN10 (Entrez ID 25814) will be associated with
Gait ataxia (HP:0002066), because mutations in that
gene cause Spinocerebellar ataxia (OMIM:603516),
which is annotated to this HPO class. The ﬁles are
constructed for different phenotype annotation
sources (OMIM, Orphanet) and different frequency
thresholds.
Other jobs generate the data used by the
Phenomizer(hpo.annotations.monthly.phenomi-
zer), a precomputed disease–disease similarity matrix
(hpo.diseasesimilarity), as well as the cross-
species phenotype resource Uberpheno (hpo.ontology
.uberpheno).
Besides these ﬁles, the information of the HPO project
can also be accessed in other ways. The HPO
Web site offers an individual page for each HPO term
(e.g. http://www.human-phenotype-ontology.org/hpoweb
/showterm?id=HP:0000127), each of which displays the
term label, synonyms, deﬁnition and links to genes and
diseases. The PhenExplorer is a Web-based application
that offers much of the same functionality in a graphical
user interface. The HPO is being increasingly used as a
basis for integrating phenotypic abnormalities into
computational algorithms for diagnostics and research.
For instance, Phenomizer (29) and BOQA (20) can be
used to assist clinical differential diagnostic for human
genetics, and MouseFinder (30), Monarch (http://
monarchinitiative.org) PhenoDigm (14) as well as
PhenomeNET (12) enable searches for novel disease
genes based on the analysis of model-organism pheno-
types. The HPO has been used to integrate phenotypic
information into computational analysis of the distribu-
tion of proteins in the postsynaptic density of the human
neocortex (31), to derive a disease–disease similarity
measure for the prediction of novel drug indications (32)
and to analyze overrepresentation of phenotypes
associated with individual protein domains (33). A
summary of tools and applications using data from the
HPO project is given in Table 5.
The HPO project offers a number of ﬁles that are in-
tended to help users use these kinds of data for their own
research. A Hudson job (hpo.diseasesimilarity)
creates a precomputed disease similarity matrix, which
contains all diseases that have annotations to the HPO
subontology ‘phenotypic abnormality’. The similarity
value between two diseases is calculated using the HPO
annotations for the diseases to calculate a semantic simi-
larity measure (6). A symmetric and an asymmetric
version of the disease similarity matrix are calculated
(29,35).
The HPO tracker at http://purl.obolibrary.org/obo/
hp/tracker can be used to request new classes or to
suggest structural changes of the HPO subsumption
hierarchy.
Classes of the HPO and associated diseases and genes
can be accessed using persistent URLs of the form http://
purl.obolibrary.org/obo/HP_ID, where <ID> represents
the numeric identiﬁer of the HPO class. Further informa-
tion on HPO-related publications and general announce-
ments can be found on the HPO Web site at http://www.
human-phenotype-ontology.org.
Table 5. Tools and applications using HPO
Tool Reference/URL
Differential diagnosis and exome analysis
Phenomizer (29)
BOQA (20)
Exomiser http://www.sanger.ac.uk/
resources/databases/exomiser/
Clinical data management and analysis
Cartagenia http://www.cartagenia.com/
ECARUCA (26)
DECIPHER (18)
PhenoTips (34)
Cross-species phenotype analysis
PhenoDigm (14)
MouseFinder (30)
Monarch http://monarchinitiative.org
PhenomeNet (12)
Uberpheno (13)
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FUTURE DEVELOPMENTS
Development of the HPO has continued apace since its
initial publication in 2008 (6). The HPO has focused on
providing a well-deﬁned, comprehensive and interoperable
resource for computational analysis of human disease
phenotypes and has been used as a basis for a wide
panoply of tools to perform analysis in clinical and in
research settings. While the initial focus of the HPO was
placed on rare, mainly Mendelian diseases, HPO annota-
tions are now available also for CNV diseases, and a pilot
project to explore the development of annotations for
common diseases is currently underway.
Deep phenotyping has been deﬁned as the precise and
comprehensive analysis of phenotypic abnormalities in
which the individual components of the phenotype are
observed and described (36). Deep phenotype analysis is
an essential component of the emerging ﬁeld of precision
medicine, which aims to provide the best available care for
each patient based on stratiﬁcation into disease subclasses
with a common biological basis of disease. The HPO aims
to provide a powerful and manually curated resource to
support efforts to discover disease subclasses, and to
translate this knowledge into clinical care, by providing
the means to capture, store and exchange phenotypic
data. The clinical data that have been captured in this
fashion are computable and can be easily integrated into
computational algorithms for translational biomedical
research.
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